Influenza News and Research

Latest Influenza News and Research

Molecular virologist uses basic science to fight influenza

Molecular virologist Chad Petit, Ph.D., uses basic science to fight influenza -- through experiments at the atomic level.

3 Nov 2018

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Ark Biosciences, a biotech company developing proprietary therapeutics for viral infection and respiratory diseases, announced today the significant progress in its phase 2 proof-of-concept study of ziresovir in the treatment of hospitalized RSV infected infants.

1 Nov 2018

New study to evaluate human immune system's response to influenza

The key to lasting protection against influenza may be in your bones. The cells that naturally protect you against illness originate and live in your bone marrow - and that is one spot where scientists will be looking to understand the human immune system's response to influenza in a groundbreaking new study led by the Human Vaccines Project.

1 Nov 2018

Scientists discover cell adhesion mechanism used by mycoplasma genitalium

Researchers from the Molecular Biology Institute of Barcelona and the Institute of Biotechnology and Biomedicine have discovered the mechanism by which the bacterium Mycoplasma genitalium) adheres to human cells.

29 Oct 2018

Influenza virus can evolve resistance to experimental antiviral drug

The influenza virus can evolve resistance to an anti-flu drug currently in development for use in pandemics but only if there are multiple genetic mutations, a study has found.

25 Oct 2018

Battling against resistant and sensitive types of influenza A

Another flu season is here, which means another chance for viruses to mutate. Already, most influenza A viruses contain a mutation that confers resistance against one class of antiviral medications, and the bugs are steadily gaining resistance against another class.

25 Oct 2018

FDA approves new antiviral flu treatment

Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

24 Oct 2018

High-dose influenza vaccine associated fewer hospitalizations in dialysis patients

Results from a new study suggest that high-dose influenza vaccine is associated with lower risk for hospitalizations in kidney failure patients on dialysis. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology

24 Oct 2018

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex's entire infectious disease vaccine platform.

24 Oct 2018

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.

23 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery

UT Southwestern biochemist Dr. Zhijian "James" Chen today was named winner of the prestigious 2019 Breakthrough Prize in Life Sciences for his discovery of the cGAS enzyme that launches the body's immune defense against infections and cancers.

19 Oct 2018

New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses

Researchers developed a novel DNA influenza vaccine based on four micro-consensus antigenic regions selected to represent the diversity of seasonal H3N2 viruses across decades.

18 Oct 2018

Researchers develop new techniques for faster detection of Lyme disease bacteria

Researchers have developed techniques to detect Lyme disease bacteria weeks sooner than current tests, allowing patients to start treatment earlier.

11 Oct 2018

NIR spectroscopy could be used to make flu vaccine manufacturing faster and more efficient

Recent research from North Carolina State University outlines how near-infrared spectroscopy could be used to make cell-culture-based flu vaccine manufacturing faster and more efficient.

11 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

Immune protein 'flutters' like a butterfly in search of viruses, finds study

Researchers at Rutgers Robert Wood Johnson Medical School have identified an important step in the process that allows our bodies to fight viruses.

2 Oct 2018

Scientists investigate effect of flu-causing virus on three lung-derived cell lines

Perhaps inspired by the annual 3 to 5 million cases of severe influenza worldwide, the Guinness World Record organization is advertising for individuals or organizations to attempt a record for the most people getting a flu awareness lesson at once.

29 Sep 2018

Influenza News and Research

Latest Influenza News and Research

Molecular virologist uses basic science to fight influenza

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

New study to evaluate human immune system's response to influenza

Scientists discover cell adhesion mechanism used by mycoplasma genitalium

Influenza virus can evolve resistance to experimental antiviral drug

Battling against resistant and sensitive types of influenza A

FDA approves new antiviral flu treatment

High-dose influenza vaccine associated fewer hospitalizations in dialysis patients

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery

New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses

Researchers develop new techniques for faster detection of Lyme disease bacteria

NIR spectroscopy could be used to make flu vaccine manufacturing faster and more efficient

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Immune protein 'flutters' like a butterfly in search of viruses, finds study

Scientists investigate effect of flu-causing virus on three lung-derived cell lines

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Influenza News and Research

Latest Influenza News and Research

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in